Administration of single-dose GnRH agonist in the luteal phase in ICSI cycles: A meta-analysis

Reproductive Biology and Endocrinology

Volumn 8, Issue , 2010, Pages

  Oliveira, João B A ^a,b,c   Baruffi, Ricardo ^b,c   Petersen, Cláudia G ^a,b,c   Mauri, Ana L ^b,c   Cavagna, Mario ^b   Franco Jr, José G ^a,b,c  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^b Center for Human Reproduction Prof Franco Junior   (Brazil)

^c Paulista Center for Diagnosis Research and Training   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BUSERELIN; CETRORELIX; CHORIONIC GONADOTROPIN; ESTRADIOL VALERATE; GANIRELIX; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; HUMAN MENOPAUSAL GONADOTROPIN; LEUPRORELIN; PLACEBO; PROGESTERONE; RECOMBINANT CHORIONIC GONADOTROPIN; RECOMBINANT FOLLITROPIN; TRIPTORELIN; DESLORELIN; DRUG DERIVATIVE; FERTILITY PROMOTING AGENT; GONADORELIN;

CLINICAL TRIAL; DRUG EFFECT; EMBRYO TRANSFER; FERTILIZATION IN VITRO; HUMAN; INFERTILITY; INTRACYTOPLASMIC SPERM INJECTION; LOW DRUG DOSE; LUTEAL PHASE; META ANALYSIS; NIDATION; OVULATION INDUCTION; PREGNANCY RATE; REVIEW; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; ALGORITHM; DOSE RESPONSE; DRUG POTENTIATION; FEMALE; METHODOLOGY; PREGNANCY; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICS;

ALGORITHMS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FERTILITY AGENTS, FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; INFERTILITY; LUTEAL PHASE; OVULATION INDUCTION; PREGNANCY; PREGNANCY RATE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SPERM INJECTIONS, INTRACYTOPLASMIC; TREATMENT OUTCOME; TRIPTORELIN;

EID: 77956455557     PISSN: None     EISSN: 14777827     Source Type: Journal    
DOI: 10.1186/1477-7827-8-107     Document Type: Review

References (40)

1. Devroey P, Bourgain C, Macklon NS, Fauser BC. Reproductive biology and IVF: ovarian stimulation and endometrial receptivity. Trends Endocrinol Metab 2004, 15:84-90. 10.1016/j.tem.2004.01.009, 15036255.
2. Fatemi HM, Popovic-Todorovic B, Papanikolaou E, Donoso P, Devroey P. An update of luteal phase support in stimulated IVF cycles. Hum Reprod Update 2007, 13:581-590. 10.1093/humupd/dmm021, 17626114.
3. Pritts EA, Atwood AK. Luteal phase support in infertility treatment: a meta-analysis of the randomized trials. Hum Reprod 2002, 17:2287-2299. 10.1093/humrep/17.9.2287, 12202415.
4. Lemay A, Faure N, Labrie F. Sensitivity of pituitary and corpus luteum responses to single intranasal administration of (D-ser[TBU]6-des-gly-NH2(10)) luteinizing hormone-releasing hormone ethylamide (Buserelin) in normal women. Fertil Steril 1982, 37:193-200.
5. Lemay A, Faure N, Labrie F, Fazekas AT. Gonadotroph and corpus luteum responses to two successive intranasal doses of a luteinizing hormone-releasing hormone agonist at different days after the midcycle luteinizing hormone surge. Fertil Steril 1983, 39:661-667.
6. Dubourdieu S, Charbonnel B, Massai MR, Marraoui J, Spitz I, Bouchard P. Suppression of corpus luteum function by the gonadotropin-releasing hormone antagonist Nal-Glu: effect of the dose and timing of human chorionic gonadotropin administration. Fertil Steril 1991, 56:440-445.
7. Herman A, Ron-El R, Golan A, Nachum H, Soffer Y, Caspi E. Impaired corpus luteum function and other undesired results of pregnancies associated with inadvertent administration of a long-acting agonist of gonadotrophin-releasing hormone. Hum Reprod 1992, 7:465-468.
8. Nillius SJ. Luteinizing hormone releasing hormone analogues for contraception. Clin Obstet Gynaecol 1984, 11:551-572.
9. Thau RB. Luteinizing hormone-releasing hormone (LHRH) and its analogs for contraception in women: a review. Contraception 1984, 29:143-162. 10.1016/0010-7824(84)90025-8, 6426857.
10. Balasch J, Martinez F, Jove I, Cabre L, Coroleu B, Barri PN, Vanrell JA. Inadvertent gonadotrophin-releasing hormone agonist (GnRHa) administration in the luteal phase may improve fecundity in in-vitro fertilization patients. Hum Reprod 1993, 8:1148-1151.
11. Cahill DJ, Fountain SA, Fox R, Fleming CF, Brinsden PR, Hull MG. Outcome of inadvertent administration of a gonadotrophin-releasing hormone agonist (buserelin) in early pregnancy. Hum Reprod 1994, 9:1243-1246.
12. Papanikolaou EG, Platteau P, Albano C, Kolibianakis E, Devroey P. Achievement of pregnancy three times in the same patient during luteal GnRH agonist administration. Reprod Biomed Online 2005, 10:347-349. 10.1016/S1472-6483(10)61794-4, 15820040.
13. Platteau P, Gabbe M, Talbot M, Healy D. Two consecutive pregnancies during inadvertent gonadotropin-releasing hormone agonist desensitization. Fertil Steril 2000, 73:1244-1246. 10.1016/S0015-0282(00)00536-7, 10856492.
14. Tan HH, Yeong CT, Loh KE. Perinatal outcome of pregnancies after inadvertent exposure to gonadotrophin-releasing hormone analogue. Aust N Z J Obstet Gynaecol 2006, 46:336-340. 10.1111/j.1479-828X.2006.00602.x, 16866796.
15. Isik AZ, Caglar GS, Sozen E, Akarsu C, Tuncay G, Ozbicer T, Vicdan K. Single-dose GnRH agonist administration in the luteal phase of GnRH antagonist cycles: a prospective randomized study. Reprod Biomed Online 2009, 19:472-477. 10.1016/j.rbmo.2009.04.001, 19909586.
16. Razieh DF, Maryam AR, Nasim T. Beneficial effect of luteal-phase gonadotropin-releasing hormone agonist administration on implantation rate after intracytoplasmic sperm injection. Taiwan J Obstet Gynecol 2009, 48:245-248. 10.1016/S1028-4559(09)60297-7, 19797013.
17. Tesarik J, Hazout A, Mendoza C. Enhancement of embryo developmental potential by a single administration of GnRH agonist at the time of implantation. Hum Reprod 2004, 19:1176-1180. 10.1093/humrep/deh235, 15070873.
18. Tesarik J, Hazout A, Mendoza-Tesarik R, Mendoza N, Mendoza C. Beneficial effect of luteal-phase GnRH agonist administration on embryo implantation after ICSI in both GnRH agonist- and antagonist-treated ovarian stimulation cycles. Hum Reprod 2006, 21:2572-2579. 10.1093/humrep/del173, 16926261.
19. Fujii S, Sato S, Fukui A, Kimura H, Kasai G, Saito Y. Continuous administration of gonadotrophin-releasing hormone agonist during the luteal phase in IVF. Hum Reprod 2001, 16:1671-1675. 10.1093/humrep/16.8.1671, 11473961.
20. Qublan H, Amarin Z, Al-Qudah M, Diab F, Nawasreh M, Malkawi S, Balawneh M. Luteal phase support with GnRH-a improves implantation and pregnancy rates in IVF cycles with endometrium of
21. Pirard C, Donnez J, Loumaye E. GnRH agonist as novel luteal support: results of a randomized, parallel group, feasibility study using intranasal administration of buserelin. Hum Reprod 2005, 20:1798-1804. 10.1093/humrep/deh830, 15890740.
22. Pirard C, Donnez J, Loumaye E. GnRH agonist as luteal phase support in assisted reproduction technique cycles: results of a pilot study. Hum Reprod 2006, 21:1894-1900. 10.1093/humrep/del072, 16556673.
23. Ata B, Urman B. Single dose GnRH agonist administration in the luteal phase of assisted reproduction cycles: is the effect dependent on the type of GnRH analogue used for pituitary suppression?. Reprod Biomed Online 2010, 20:165-166. 10.1016/j.rbmo.2009.10.022, 20159003.
24. Ata B, Yakin K, Balaban B, Urman B. GnRH agonist protocol administration in the luteal phase in ICSI-ET cycles stimulated with the long GnRH agonist protocol: a randomized, controlled double blind study. Hum Reprod 2008, 23:668-673. 10.1093/humrep/dem421, 18192671.
25. Isikoglu M, Ozgur K, Oehninger S. Extension of GnRH agonist through the luteal phase to improve the outcome of intracytoplasmic sperm injection. J Reprod Med 2007, 52:639-644.
26. Casan EM, Raga F, Polan ML. GnRH mRNA and protein expression in human preimplantation embryos. Mol Hum Reprod 1999, 5:234-239. 10.1093/molehr/5.3.234, 10333357.
27. Kawamura K, Fukuda J, Kumagai J, Shimizu Y, Kodama H, Nakamura A, Tanaka T. Gonadotropin-releasing hormone I analog acts as an antiapoptotic factor in mouse blastocysts. Endocrinology 2005, 146:4105-4116. 10.1210/en.2004-1646, 15932933.
28. Nam DH, Lee SH, Kim HS, Lee GS, Jeong YW, Kim S, Kim JH, Kang SK, Lee BC, Hwang WS. The role of gonadotropin-releasing hormone (GnRH) and its receptor in development of porcine preimplantation embryos derived from in vitro fertilization. Theriogenology 2005, 63:190-201. 10.1016/j.theriogenology.2004.04.004, 15589284.
29. Raga F, Casan EM, Kruessel J, Wen Y, Bonilla-Musoles F, Polan ML. The role of gonadotropin-releasing hormone in murine preimplantation embryonic development. Endocrinology 1999, 140:3705-3712. 10.1210/en.140.8.3705, 10433230.
30. Islami D, Chardonnens D, Campana A, Bischof P. Comparison of the effects of GnRH-I and GnRH-II on HCG synthesis and secretion by first trimester trophoblast. Mol Hum Reprod 2001, 7:3-9. 10.1093/molehr/7.1.3, 11134354.
31. Lin LS, Roberts VJ, Yen SS. Expression of human gonadotropin-releasing hormone receptor gene in the placenta and its functional relationship to human chorionic gonadotropin secretion. J Clin Endocrinol Metab 1995, 80:580-585. 10.1210/jc.80.2.580, 7852524.
32. Klemmt PA, Liu F, Carver JG, Jones C, Brosi D, Adamson J, Mardon HJ, McVeigh E. Effects of gonadotrophin releasing hormone analogues on human endometrial stromal cells and embryo invasion in vitro. Hum Reprod 2009, 24:2187-2192. 10.1093/humrep/dep181, 2727401, 19520710.
33. Raga F, Casan EM, Kruessel JS, Wen Y, Huang HY, Nezhat C, Polan ML. Quantitative gonadotropin-releasing hormone gene expression and immunohistochemical localization in human endometrium throughout the menstrual cycle. Biol Reprod 1998, 59:661-669. 10.1095/biolreprod59.3.661, 9716567.
34. Shemesh M. Actions of gonadotrophins on the uterus. Reproduction 2001, 121:835-842. 10.1530/rep.0.1210835, 11373169.
35. Chou CS, Tai CJ, MacCalman CD, Leung PC. Dose-dependent effects of gonadotropin releasing hormone on matrix metalloproteinase (MMP)-2, and MMP-9 and tissue specific inhibitor of metalloproteinases-1 messenger ribonucleic acid levels in human decidual Stromal cells in vitro. J Clin Endocrinol Metab 2003, 88:680-688. 10.1210/jc.2002-021277, 12574199.
36. Raga F, Casan EM, Wen Y, Huang HY, Bonilla-Musoles F, Polan ML. Independent regulation of matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1 (TIMP-1), and TIMP-3 in human endometrial stromal cells by gonadotropin-releasing hormone: implications in early human implantation. J Clin Endocrinol Metab 1999, 84:636-642. 10.1210/jc.84.2.636, 10022430.
37. Meresman GF, Bilotas MA, Lombardi E, Tesone M, Sueldo C, Baranao RI. Effect of GnRH analogues on apoptosis and release of interleukin-1beta and vascular endothelial growth factor in endometrial cell cultures from patients with endometriosis. Hum Reprod 2003, 18:1767-1771. 10.1093/humrep/deg356, 12923126.
38. Wu HM, Wang HS, Huang HY, Soong YK, MacCalman CD, Leung PC. GnRH signaling in intrauterine tissues. Reproduction 2009, 137:769-777. 10.1530/REP-08-0397, 19208750.
39. Zhang X, Bocca S, Franchi A, Anderson S, Kaur M, Bajic VB, Oehninger S. Do GnRH analogues directly affect human endometrial epithelial cell gene expression?. Mol Hum Reprod 2010, 16:347-360. 10.1093/molehr/gaq012, 20203127.
40. Hugues JN, Cedrin-Durnerin I, Bstandig B, Theron-Gerard L, Grange D, Laffy A, Clement P, Hamidi J, Sifer C, Poncelet C. Administration of gonadotropin-releasing hormone agonist during the luteal phase of GnRH-antagonist IVF cycles. Hum Reprod 2006, 21:i3.